This research reveals potent acetylcholinesterase inhibition in synthesized multitarget ligands, suggesting potential for Alzheimer's therapy.
Key Points
The coumarin derivatives showed acetylcholinesterase inhibition with IC50 values ranging from 4 to 104 nM, indicating strong potency.
Kinetic studies revealed mixed-type inhibition with significant selectivity over butyrylcholinesterase, enhancing their therapeutic value.
Selected compounds demonstrated non-neurotoxicity and neuroprotective effects at low concentrations, suggesting safety profiles for further development.
The multitarget profile includes interactions with H3R and monoamine oxidases, indicating potential for complex therapeutic effects in Alzheimer’s disease.